Dow Shares Solutions to Advance Human Progress

The Dow Chemical Company continues to be a differentiated technology solutions provider in the healthcare and medical markets sectors, collaborating closely with customers at all points of the value chain to address current and future market challenges. Dow leverages its industry-leading scientific, engineering and business expertise to deliver active ingredients, excipients, and reagents consistently and reliably anywhere in the world.

Drug formulators, pharmaceutical companies and others visiting Dow at CPhI Worldwide can learn more about the company’s extensive capabilities in helping to create and refine APIs, its expertise in ingredients for drug formulation and delivery and how Dow is helping to develop the next generation of solutions to advance human progress.

Specific solutions and offerings to be highlighted at CPhI 2013 include:

• METHOCEL DC2, a next-generation excipient designed to help pharmaceutical manufacturers shorten development time and lower manufacturing costs up to 60%.

• AFFINISOL, a portfolio of solubility enhancement solutions designed to help bring insoluble APIs to the market, including:

— AFFINISOL HPMCAS with many substitution options available reportedly beyond products commercially available today

— New AFFINISOLTM HPMCAS High Productivity for higher throughput in spray-drying

— New AFFINISOL HPMC with improved thermoplastic properties for hot melt extrusion.

• CARBOWAX SENTRY polyethylene glycols for applications ranging from APIs in laxatives and colonic lavage formulations to versatile excipients used in tablets, ointments, creams, gelatin capsules, liquid medications and suppositories.

• AMBERLITE and DUOLITE functional ion exchange excipients that help improve the delivery of drugs by offering formulation flexibility in key areas such as taste masking, controlled release and abuse deterrence.

• High-quality borohydride reducing agents for fine chemical synthesis, offered under the VENPURE brand.

Show participants are also encouraged to attend Dow’s presentation on innovative solutions designed to enhance the bioavailability of poorly soluble APIs, given by Dr. Amina Faham, Senior Pharmaceutical Development Application Manager. Dr. Faham will discuss how employing science-based formulation strategies can offer clear line of sight to the commercialisation of drugs on Wednesday 23 October, at CPhI Speaker's Corner. 

Stand 61C67.

The Dow Chemical Company, www.dow.com.